Anti-HA [CR8020]

Absolute Antibody

Anti-HA [CR8020]

7

This antibody binds hemaglutinin of most group 2 influenza viruses including H3N2 and H7N7.

CR8020 has a broad neutralizing activity against most group 2 viruses, including H3N2 and H7N7. The crystal structure of Fab CR8020 with the 1968 pandemic H3 hemagglutinin (HA) reveals a highly conserved epitope in the HA stalk distinct from the epitope recognized by the VH1-69 group 1 antibodies. CR8020 binds most group 2 HAs with high affinity, including H3 isolates. Flow cytometry was used to test the ability of the antibody to bind different structural HA conformations of recombinant influenza A subtype H3. Therapeutic treatment with 15 mg/kg of CR8020 up to 2 days after infection with H3N2 completely prevented mortality, whereas 50% of the mice treated 3 days after infection were protected (PMID: 21737702). It is reported that Oseltamivir/Zanamivir may congruously improve the therapeutic efficacy of CR8020 (PMID: 22693576).

Flow Cytometry, Neutralisation/Blocking

NTRL; Therapeutic; FC

Research Use Only

Monoclonal

CR8020

Rabbit

IgG

Hemagglutinin

This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.

Virus

Influenza A virus (several subtypes)

The original antibody was generated from the PBMCs of donors vaccinated 7 days earlier with the trivalent inactivated influenza vaccine for the 2006-2007 season (containing A/New Caledonia/20/1999 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004).

-20°C,2°C to 8°C

12352203